Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic, Wegovy, ...

Beta Bionics hit net sales of $44.7m in the first nine months of 2024, marking an increase from $3.6m in 2023. Beta Bionics’ ...

Shares in the Irvine-based medical device company rose 29% to $23.64 and a $975 million market within the first three hours ...

The FDA has approved Ozempic to reduce kidney failure risk in people with type 2 diabetes and chronic kidney disease. Studies ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

Infinity Natural Resources Inc. priced its initial public offering above the midpoint of its range in a sign of a strong stock-market debut for the oil and gas producer, which operates in Ohio and ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

More children should be screened for Type 1 diabetes. That’s the message from an international team led by University of ...